1. Homocyst(e)ine and Coronary Heart Disease

   • Brahmajee K. Nallamothu
   • A. Mark Fendrick
   • Gilbert S. Omenn

   Review Article 22 September 2012 Pages: 429 - 442

   

2. Standardisation of Costs

   • Jan B. Oostenbrink
   • Marc A. Koopmanschap
   • Frans F. H. Rutten

   Review Article 22 September 2012 Pages: 443 - 454

   

3. Health-Related Quality of Life and Cost Impact of Irritable Bowel Syndrome in a UK Primary Care Setting

   • Ron L. Akehurst
   • John E. Brazier
   • Stephen J. Walters

   Original Research Article 22 September 2012 Pages: 455 - 462

   

4. Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year Values

   • Gérard Duru
   • Jean Paul Auray
   • Nicolas Nicoloyannis

   Original Research Article 22 September 2012 Pages: 463 - 473

   

5. A Model to Estimate the Cost Benefit of an Occupational Vaccination Programme for Influenza with Influvac® in the UK

   • Roben Das Gupta
   • Julian F. Guest

   Original Research Article 22 September 2012 Pages: 475 - 484

   

6. Cost Effectiveness of Paclitaxel/Cisplatin Compared with Cyclophosphamide/Cisplatin in the Treatment of Advanced Ovarian Cancer in Belgium

   • Niels Neymark
   • Thierry Gorlia
   • Martine Piccart

   Original Research Article 22 September 2012 Pages: 485 - 497